Companies Dominating the Diabetic Neuropathy market
- Hoffmann-La Roche Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott Laboratories
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- GlaxoSmithKline plc
- Lupin Limited
- Glenmark Pharmaceuticals Limited
- Assertio Holdings, Inc.
- Astellas Pharma US, Inc.
- Pfizer Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Diabetic Neuropathy Market in 2025 is evaluated at USD 6.32 billion.
The global market size exceeded USD 5.91 billion in 2024 and is set to expand at a CAGR of over 8.7%, surpassing USD 17.48 billion revenue by 2037.
North America is on pace to secure majority share by 2037, owing to rising prevalence of diabetes and the increasing geriatric population.
The major players in the market include Hoffmann-La Roche Ltd., Abbott Laboratories, Eli Lilly and Company, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Lupin Limited, Glenmark Pharmaceuticals Limited, Assertio Holdings, Inc., Astellas Pharma US, Inc., Pfizer Inc.
